general interest

Translational research bridges the gap between scientific discoveries and real-world applications, transforming scientific breakthroughs into life-changing therapies. Success in this endeavor hinges on several factors, including collaboration between scientists and clinicians. A notable example of this is the approval of Zolgensma, a gene therapy for spinal muscular atrophy (SMA), which marked a significant milestone in the field of translational research.

The differences between us are what makes life interesting, and diversity in a group that shares a common goal can lead to many benefits. Here we examine the similarities and differences between researchers using flow cytometry for academic research and those using it for drug discovery. We outline the challenges they face and learn that they share a common goal as well as a common solution.

The Pioneer Platform features one of the largest functional antibody libraries available, utilizing SpyLock technology for rapid prototyping and screening of hundreds of bispecific antibodies, and TrailBlazer technology for efficient antibody format conversion. Together, these services provide a comprehensive and streamlined solution for researchers seeking to develop innovative biotherapeutic therapies.

As technology advances, a digital transformation has begun in laboratories around the world. Driven by the need to improve data quality and increase the value derived from the investment in generating those data, data management systems, devices, and their workflows are becoming more connected and integrated, ushering in the age of the digital laboratory. The digital laboratory is one where paper lab notebooks are replaced with fully digital data, complete with rich metadata, and generated using integrated workflows. Such data are easy to find, reuse, and reproduce. Further digitization and workflow integration to operate laboratory instruments will advance the burgeoning digital laboratory.

It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.

Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.

In 2017, Bioradiations published a wide variety of general interest articles, tips, podcasts, and application notes. Revisit the technological advancements and growth in technology that researchers experienced this year. Here are the highlights of what we learned this year.

Explore the most watched Bio-Rad videos in 2017. From understanding CRISPR gene editing to generating better qPCR data to selecting antibodies for fluorescent western blotting, these videos highlight how we continually strive to help our customers do better science.

2017 saw the launch of Bioradiations’ first-ever podcast! Here you can listen to the top five podcasts we published this year, and learn about a variety of topics from CRISPR gene editing to what biomarkers and biosimilars are.

Stem cells possess the remarkable potential to self-renew and to differentiate into many different types of cells. Due to their unique ability to regenerate, they are being used in regenerative medicine and offer great hope for treating diseases such as diabetes and heart disease. However, since stem cells represent a rare population of cells, they are not always easy to study. See how the simplicity, efficiency, and flexibility of cell sorting is making it possible to isolate pure populations of stem cells for downstream analyses.